12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Livatag doxorubicin Transdrug: Phase III ongoing

BioAlliance said an independent DSMB recommended continuation of the open-label, international Phase III ReLive trial of Livatag based on safety data from the first 6 months. ReLive is evaluating 20 and...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >